RenovoRx, Inc. (RNXT) Stock Profile — Insider Trades & Financials

EPS$-0.24

Market Cap$42.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Shaun Bagai

CEO & Executive Director

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Founded: 2012
Employees: 10
Headquarters: Mountain View, California, United States
Website

⚡

Core Efficiency

D/E Ratio?

0.49

📊

Profitability Ratios

Current Ratio?

4.02

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 30, 2026 (in 143 days)

Annual Report (10-K) — Based on filing pattern

Aug 30, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 2025-1d after period end

Nov 13, 2025

10-QQ3 20251d after period end

Aug 14, 2025

10-QQ2 20253d after period end

May 15, 2025

10-QQ1 20256d after period end

Apr 1, 2025

10-KQ4 20247d after period end

Nov 13, 2024

10-QQ3 20246d after period end

Aug 13, 2024

10-QQ2 20248d after period end

May 10, 2024

10-QQ1 20242d after period end

Loading company sections...

RenovoRx, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness